Zuellig Pharma (B): Putting transformation to the test
Case (B) is set in January 2020 when CEO John Davison decided to step down as CEO by end of June 2020. It describes the specific actions of Zuellig Pharma’s transformation and how they resulted in more than doubling the company’s net profit between 2015 and 2019 These actions included: (1) driving operational excellence by successfully completing the ERP implementation and taking other steps to fix operational problems; (2) fostering the leadership team through selective changes and aligning it around an integrated regional strategy; (3) increasing head office control while ensuring that country operations had the autonomy needed to operate effectively; (4) resetting the relationship between the management and the board to create more alignment and trust; (5) strengthening relationships with key distribution clients; and (6) growing the solutions businesses which accounted by 2019 for over 20% of GOR and net profit. The case also describes the situation facing Zuellig Pharma as the Covid-19 pandemic began to unfold, and John Davison’s initial thoughts on related key issues facing the company.
- Crisis management in the face of the COVID-19 pandemic.
- Resilience: Individual resilience as a leader as well as organizational and IT system resilience.
- Succession planning
Zuellig Pharma, Healthcare, Pharmaceuticals
2014 – 2020
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
- Zuellig Pharma (A): A case for transformation
- Zuellig Pharma (B): Putting transformation to the test
- Zuellig Pharma (C): Taking the next leap
- Zuellig Pharma (A): A case for transformation
- Zuellig Pharma (B): Putting transformation to the test
- Zuellig Pharma (C): Taking the next leap
Case reference: IMD-7-2240 ©2020
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-7-2241 ©2020
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-7-2242 ©2020
Research Information & Knowledge Hub for additional information on IMD publications
This is a riveting case about poor board governance at Theranos that fostered a culture of deception and led to the company's collapse and the criminal conviction of its celebrated founder, Elizabeth Holmes. Case B explains Theranos's eventual col...
Shenzhen Power-Solution (SPS), founded in 2009 in China as an entrepreneurial venture, disrupted traditional lighting markets in African villages with its flagship product, Candles Killer. This solar lamp, priced under $5, replaces hazardous keros...
This is a riveting case about poor board governance at Theranos that fostered a culture of deception and led to the company's collapse and the criminal conviction of its celebrated founder, Elizabeth Holmes. Case A outlines the establishment and g...
This note provides a comprehensive framework for understanding and developing the core interpersonal processes essential for effective leadership. It identifies and explores seven key processes: Communication, Visioning, Alliance Building, Persuas...
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
This is a riveting case about poor board governance at Theranos that fostered a culture of deception and led to the company's collapse and the criminal conviction of its celebrated founder, Elizabeth Holmes. Case A outlines the establishment and g...
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
This is a riveting case about poor board governance at Theranos that fostered a culture of deception and led to the company's collapse and the criminal conviction of its celebrated founder, Elizabeth Holmes. Case B explains Theranos's eventual col...
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications